1. 64. EORTC-1203: Integration of trastuzumab, with or without pertuzumab, into perioperative chemotherapy of HER-2 positive stomach cancer: INNOVATION EudraCT number 2014-000722-38; NCT02205047. Issue 9 (September 2016) Authors: Wagner, A.D.; Kang, Y.K.; Van Dieren, J.; Mauer, M.; Grabsch, H.; Caballero, C.; Kataoka, K.; Atasoy, A.; Cho, J.Y.; Mohler, M.; Roth, A.; Salto-Tellez, M.; Langer, R.; Schuhmacher, C.; Van Sandick, J.; Van Grieken, N.; Lordick, F. Journal: European journal of surgical oncology Issue: Volume 42:Issue 9(2016:Sep.) Page Start: S91 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 2118 Quality of life (QoL) during second-line treatment with FOLFIRI +/- panitumumab (pmab) in patients (pts) with RAS wild-type (WT) metastatic colorectal carcinoma (mCRC). (September 2015) Authors: Sobrero, A.F.; Price, T.J.; Cervantes, A.; Ducreux, M.; Andre, T.; Lordick, F.; Punt, C.J.; Hechmati, G.; Demonty, G.; Koukakis, R.; Peeters, M. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S369 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. SP-0022 New systemic treatments in non-metastasised oesophageal cancer. (May 2022) Authors: Lordick, F. Journal: Radiotherapy and oncology Issue: Volume 170(2022)Supplement 1 Page Start: S6 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. ESMO pays tribute to Professor José Baselga. (March 2021) Authors: Peters, S.; Tabernero, J.; Cervantes, A.; Banerjee, S.; Giuliani, R.; Lordick, F. Journal: Immuno-oncology technology Issue: Volume 9(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. The multidisciplinary management of gastro-oesophageal junction tumours: European Society of Digestive Oncology (ESDO): Expert discussion and report from the 16th ESMO World Congress on Gastrointestinal Cancer, Barcelona. Issue 11 (November 2016) Authors: Van Laethem, J.-L.; Carneiro, F.; Ducreux, M.; Messman, H.; Lordick, F.; Ilson, D.H.; Allum, W.H.; Haustermans, K.; Lepage, C.; Matysiak-Budnik, T.; Cats, A.; Schmiegel, W.; Cervantes, A.; Van Cutsem, E.; Rougier, Ph.; Seufferlein, Th. Journal: Digestive and liver disease Issue: Volume 48:Issue 11(2016) Page Start: 1283 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Response-adapted treatment stratification in oesophago-gastric cancer. (March 2018) Authors: Lordick, F. Journal: European journal of cancer Issue: Volume 92(2018)Supplement 2 Page Start: S3 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 2200 TOPGEAR: A randomized phase M/MI trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer. Interim results from an international, intergroup trial of the AGITG/TROG/NCIC CTG/EORTC. Issue 3 (September 2015) Authors: Leong, T.; Smithers, B.M.; Michael, M.; Gebski, V.; Simes, J.; Boussioutas, A.; Miller, D.; Zalcberg, J.; O'Connell, R.; Swallow, C.; Darling, G.; Wong, R.; Schuhmacher, C.; Lordick, F.; Haustermans, K. Journal: European journal of cancer Issue: Volume 51:Issue 3(2015:Feb.) Page Start: S399 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Surgery in oesophago-gastric cancer with metastatic disease: Treatment, prognosis and preoperative patient selection. Issue 10 (October 2015) Authors: Schmidt, T.; Alldinger, I.; Blank, S.; Klose, J.; Springfeld, C.; Dreikhausen, L.; Weichert, W.; Grenacher, L.; Bruckner, T.; Lordick, F.; Ulrich, A.; Büchler, M.W.; Ott, K. Journal: European journal of surgical oncology Issue: Volume 41:Issue 10(2015:Oct.) Page Start: 1340 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Identification of predictive response and resistance factors to targeted therapy in gastric cancer using a systems medicine approach. (December 2016) Authors: Luber, B.; Keller, S.; Zwingenberger, G.; Ebert, K.; Maier, D.; Geier, B.; Theis, F.; Hasenauer, J.; Hug, S.; Meyer-Hermann, M.; Dehghany, J.; Walch, A.; Aichler, M.; Lordick, F.; Haffner, I. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S135 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Factors associated with non‐participation and dropout among cancer patients in a cluster‐randomised controlled trial. (30th January 2017) Authors: Roick, J.; Danker, H.; Kersting, A.; Briest, S.; Dietrich, A.; Dietz, A.; Einenkel, J.; Papsdorf, K.; Lordick, F.; Meixensberger, J.; Mössner, J.; Niederwieser, D.; Prietzel, T.; Schiefke, F.; Stolzenburg, J.‐U.; Wirtz, H.; Singer, S. Journal: European journal of cancer care Issue: Volume 27:Number 1(2018) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗